Myocardial Infarction in HIV-Infected Men Receiving Protease Inhibitors
Authors: Thomas E. Flynn, Lee A. Bricker
Journal: Annals of Internal Medicine (1999)

Letters5 October 1999Myocardial Infarction in HIV-Infected Men Receiving Protease InhibitorsThomas E. Flynn, MD and Lee A. Bricker, MDThomas E. Flynn, MDKalamazoo Center for Medical Studies of Michigan State University School of Medicine; Kalamazoo, MI 49008 (Flynn)Kalamazoo Center for Medical Studies of Michigan State University School of Medicine; Kalamazoo, MI 49008 (Bricker) and Lee A. Bricker, MDKalamazoo Center for Medical Studies of Michigan State University School of Medicine; Kalamazoo, MI 49008 (Flynn)Kalamazoo Center for Medical Studies of Michigan State University School of Medicine; Kalamazoo, MI 49008 (Bricker)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-7-199910050-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We describe four men with HIV infection who sustained myocardial infarction (two of which were fatal) after 24 to 29 months of protease inhibitor therapy. These observations confirm and extend those of Henry and colleagues (1), and they occurred in a clinic setting in which amelioration of clinical AIDS has been frequently replaced by variable features of the insulin resistance syndrome (lipodystrophy, hyperlipidemia, pancreatitis, diabetes, and, more recently, significant macrovascular disease). The four men (ages 35 to 44 years) were smokers. Two of them (Table) developed new, protease inhibitor-related hypertriglyceridemia and hypercholesterolemia. One of the four patients ...References1. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swenson L, et al . Severe premature coronary artery disease with protease inhibitors [Letter]. Lancet. 1998;351:1328. CrossrefMedlineGoogle Scholar2. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938-9. MedlineGoogle Scholar3. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [Letter]. Ann Intern Med. 1997;127:948. LinkGoogle Scholar4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al . A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8. CrossrefMedlineGoogle Scholar5. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-3. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Thomas E. Flynn, MD; Lee A. Bricker, MDAffiliations: Kalamazoo Center for Medical Studies of Michigan State University School of Medicine; Kalamazoo, MI 49008 (Flynn)Kalamazoo Center for Medical Studies of Michigan State University School of Medicine; Kalamazoo, MI 49008 (Bricker) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEvidence of Misclassification of Drug–Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)A Systematic Review of the Effects of Exercise Interventions on Body Composition in HIV+ AdultsImpaired Lipoprotein Processing in HIV Patients on Antiretroviral TherapySmoking behavior of HIV-infected patientsCoronary Heart Disease in HIV-Infected Patients: EpidemiologyAntiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studiesChanges Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid‐Lowering Drugs in HIV‐Infected Individuals and Impact on Myocardial InfarctionLipid-Lowering Efficacy and Safety After Switching to Atazanavir-Ritonavir–Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency VirusCardiovascular risk and choice of HIV drug regimenA retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemiaUse of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresRevue des signaux générés par une méthode automatisée sur 3324 cas de pharmacovigilanceAlterações metabólicas da síndrome lipodistrófica do HIVCardiovascular and endothelial disease in HIV infectionPostprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor–based or nonnucleoside reverse transcriptase inhibitor–based antiretroviral therapyAtazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresEffects of Different Types of Exercise on Body Composition and Fat Distribution in HIV-Infected Patients: A Brief ReviewInitial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patientsHIV-1 DNA burden dynamics in CD4 T cells and monocytes in patients undergoing a transient therapy interruptionInsulin Resistance and Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral TherapyTolerability and Safety of HIV Protease Inhibitors in AdultsAtazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical TrialsLong-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or AtazanavirInfarto agudo de miocardio en pacientes con infección VIHAcute myocardial infarction in patients infected with human immunodeficiency virusManagement of dyslipidemias in the age of statinsCombination Antiretroviral Therapy and the Risk of Myocardial InfarctionIncreased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected menFrequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infectionHyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and managementIncidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapyCoronary artery disease in HIV infected patientsCardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyQuantification of Insulin-Mediated Glucose Disposal in HIV-Infected Individuals: Comparison of Patients Treated and Untreated With Protease InhibitorsHIV-Associated Coronary Artery DiseaseEmerging Bone Problems in Patients Infected with Human Immunodeficiency VirusClinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapyPathogenesis of HIV-associated heart diseaseIncidence of the involvement of the cardiovascular system in HIV infectionHIV and direct damage of organsStatins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAARTManaging the care of patients infected with bloodborne diseasesLongitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected IndividualsHIV-associated Lipodystrophy Syndrome: Assessment and ManagementEpidemiology of HIV cardiac diseaseAbnormalities in Glucose and Insulin in HIV DiseaseEarly Versus Delayed Antiretroviral Therapy in Patients with HIV InfectionMetabolic Complications Associated with HIV Protease Inhibitor TherapyEvaluation and management of dyslipidemia in patients with HIV infectionEffect of dietary intervention on highly active antiretroviral therapy-related dyslipemiaPilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV-1 Infection?Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapineThe molecular basis of genetic lipodystrophiesInfección por el virus de la inmunodeficiencia humana, terapia antirretroviral de gran actividad y enfermedad cardiovascularInteractions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV InfectionHIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemiaPathogenesis of HIV‐Associated CardiomyopathyCardiology and AIDS—HAART and the ConsequencesHIV Inhibitors: Problems and RealityCardiovascular Disease Risk Factors in HIV‐Infected Patients in the HAART EraPathogenesis of HIV-associated cardiovascular complicationsCardiovascular Manifestations of HIV InfectionDisorders of Lipid Metabolism in Patients with HIV Disease Treated with Antiretroviral Agents: Frequency, Relationship with Administered Drugs, and Role of Hypolipidaemic Therapy with BezafibrateAnti-retroviral therapy, insulin resistance and lipodystrophyMolecular basis of partial lipodystrophy and prospects for therapyHyperlipidemia and inhibitors of HIV proteaseActualités sur les traitements antirétrovirauxAntiretroviral Therapy and the Lipodystrophy SyndromeAtherosclerosis in AIDS: Potential Pathogenetic Roles of Antiretroviral Therapy and HIVAcceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapyManagement of dyslipidemia in patients with HIV diseaseAdverse effects of antiretroviral therapyCoronary Artery Disease and Human Immunodeficiency Virus InfectionMetabolic and anthropometric consequences of interruption of highly active antiretroviral therapyPre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppressionCardiovascular Complications of HIVCurrent review of the metabolic and endocrine disturbances in human immunodeficiency virus infectionCurrent review of the metabolic and endocrine disturbances in human immunodeficiency virus infectionLipodystrophy Syndrome in HIV InfectionProtease inhibitorsCoronary Heart Disease in HIV-Infected Patients: EpidemiologyThe HAART-Induced Metabolic Syndrome 5 October 1999Volume 131, Issue 7Page: 548KeywordsAIDSHyperlipidemiaInsulin resistanceLipodystrophyMyocardial infarctionPancreatitisProtease inhibitor therapyProtease inhibitorsProteasesProtein metabolism ePublished: 15 August 2000 Issue Published: 5 October 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...